Forsythia fructus inhibits the mast-cell-mediated allergic inflammatory reactions

Inflammation

Volumn 27, Issue 3, 2003, Pages 129-135

  Kim, Mi Sun ^a,b   Na, Ho Jeong ^a,b   Han, Seung Woo ^a   Jin, Jong Sik ^a   Song, Un Yong ^c   Lee, Eon Jeong ^c   Song, Bong Keun ^c   Hong, Seung Heon ^a   Kim, Hyung Min ^b  

^a Wonkwang University   (South Korea)

^b Kyung Hee University   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

Forsythia fructus; Histamine; Mast cells; Oedema; Tumor necrosis factor

Indexed keywords

CALCIMYCIN; COMPOUND 48-80; FORSYTHIA FRUCTUS EXTRACT; PHORBOL 13 ACETATE 12 MYRISTATE; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; FORSYTHIA FRUCTUS; HERB; HISTAMINE RELEASE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PAW EDEMA; PERITONEUM MAST CELL;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL SURVIVAL; EDEMA; FORSYTHIA; HUMANS; HYPERSENSITIVITY; MALE; MAST CELLS; MICE; MICE, INBRED ICR; PLANT EXTRACTS; RATS;

ANIMALIA; FORSYTHIA;

EID: 0037662755     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023865727780     Document Type: Article

References (41)

1. Ozaki, Y., J. Rui, and Y. T. Tang. 2000. Antiinflammatory effect of Forsythia suspense V(AHL) and its active principle. Biol. Pharm. Bull. 23:356-357.
2. Lee, E. B. and H. J. Keum. 1988. Pharmacological studies on Forsythia fructus. Kor. J. Pharmacognosy. 19:262-269.
3. Lentsch, A. B. and P. A. Ward. 2000. Regulation of inflammatory vascular damage. J. Pathol. 190:343-348.
4. Metcalfe, D. D., D. Baram, and Y. A. Mekori. 1999. Mast cells. Physiol. Rev. 77:1033-1079.
5. Pearce, F. L. 1989. Mast cells: Function, differentiation and activation. Curr. Opin. Immunol. 1:630-636.
6. Murrant, T. and D. Bihari. 2000. Anaphylaxis and anaphylactoid reactions. Int. J. Clin. Pract. 54:322-328.
7. Krishnaswamy, G., J. Kelley, D. Johnson, G. Youngberg, W. Stone, S. K. Huang, J. Bieber, and D. S. Chi. 2001. The human mast cell: Functions in physiology and disease. Front. Biosci. 6:1109-1127.
8. Bradding, P. and S. T. Holgate. 1999. Immunopathology and human mast cell cytokines. Crit. Rev. Oncol. Hematol. 31:119-133.
9. White, M. 1999. Mediators of inflammation and the inflammatory process. J. Allergy Clin. Immunol. 103:S378-S381.
10. Guo, Y., T. Mochizuki, E. Morii, Y. Kitamura, and K. Maeyama. 1997. Role of mast cell histamine in the formation of rat paw edema: A microdialysis study. Eur. J. Pharmacol. 331:237-243.
11. Assanasen, P. and R. M. Naclerio. 2002. Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clin. Allergy Immunol. 17:101-139.
12. Kobayashi, H., T. Ishizuka, and Y. Okayama. 2000. Human mast cells and basophils as sources of cytokines. Clin. Exp. Allergy. 30:1205-1212.
13. Männel, D. N. and B. Echtenacher. 2000. TNF in the inflammatory response. Chem. Immunol. 74:141-161.
14. Meng, H., M. G. Tonnesen, M. J. Marchase, R. A. Clark, W. F. Bahou, and B. L. Gruber. 1995. Mast cells are potent regulator endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. J. Cell. Physiol. 165:40-53.
15. Iuvone, T., R. van den Bossche, F. D'Acquisto, R. Carnuccio, and A. G. Herman. 1999. Evidence that mast cell degranulation, histamine and tumor necrosis factor α release occur in LPS-induced plasma leakage in rat skin. Br. J. Pharmacol. 128:700-704.
16. Queralt, M., P. Brazis, M. Merlos, F. de Mora, and A. Puigdemont. 2000. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm. Res. 49:355-360.
17. 2B/3receptor agonists. Eur. J. Pharmacol. 395:47-50.
18. Linardi, A., S. K. Costa, G. R. da Silva, and E. Antunes. 2000. Involvement of kinins, mast cells and sensory neurons in the plasma exudation and paw oedema induced by staphylococcal enterotoxin B in the mouse. Eur. J. Pharmacol. 399:235-242.
19. Bronner, C., C. Wiggins, D. Monte, F. Marki, A. Capron, Y. Landry, and R. C. Franson. 1987. Compound 48/80 is a potent inhibitor of phospholipase C and a dual modulator of phospholiphase A2 from human platelet. Biochim. Biophys. Acta 920:301-305.
20. Grant, S. M., K. L. Goa, A. Fitton, and E. M. Sorkin. 1990. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 40:412-448.
21. Hong, S. H., M. S. Kim, J. Y. Lee, C. Y. Hwang, S. H. Baek, D. S. Han, W. Y. Jung, S. B. Seo, T. Kajiuchi, and H. M. Kim. 2001. Novel finding in inhibition of mast cell-dependent immediate-type coetaneous reactions by Gahmi-Shini-San. Clin. Chim. Acta 309:85-90.
22. Yi, J. M., M. S. Kim, S. W. Seo, K. N. Lee, C. S. Yook, and H. M. Kim. 2001. Acanthopanax senticosus root inhibits mast cell-dependent anaphylaxis. Clin. Chim. Acta. 312:163-168.
23. Kim, M. S., W. K. Lim, J. G. Cha, N. H. An, S. J. Yoo, J. H. Park, H. M. Kim, and Y. M. Lee. 2001. The activation of PI 3-K and PKC-ζ in PMA-induced differentiation of HL-60 cells. Cancer Lett. 171:79-85.
24. Furitsu, T., T. Tsujimura, T. Tono, H. Ikeda, H. Kitamura, U. Koshimizu, H. Sigahara, J. H. Butterfield, L. K. Ashman, Y. Kanayama, Y. Matsuzawa, Y. Kitamura, and Y. Kanakura. 1993. Identification of mutations in the coding sequence of the photooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736-1744.
25. Nilsson, G., T. Blom, M. Kusche-Gullberg, L. Kjellén, J. H. Butterfield, C. Sundström, K. Nilsson, and L. Hellman. 1994. Phenotypic characterization of the human mast-cell line HMC-1. Scand. J. Immunol. 39:489-498.
26. Möller, A., B. M. Henz, A. Grützkau, U. Lippert, Y. Aragane, T. Schwarz, and S. Krüger-Krasagakes. 1998. Comparative cytokine gene expression: Regulation and release by human mast cells. Immunology 93:289-295.
27. Vergnolle, N., M. D. Hollenberg, K. A. Sharkey, and J. L. Wallace. 1999. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br. J. Pharmacol. 127:1083-1090.
28. Kawabata, A., R. Kuroda, T. Minami, K. Kataoka, and M. Taneda. 1998. Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw. Br. J. Pharmacol. 125:419-422.
29. Coderre, T. J., A. I. Basbaum, and J. D. Levine. 1989. Neural control of vascular permeability: Interactions between primary afferents, mast cells, and sympathetic efferents. J. Neurophysiol. 62:48-58.
30. García, G., P. Brazís, N. Majó, L. Ferrer, F. de Mora, and A. Puigdemont. 1997. Comparative morphofunctional study of dispersed mature canine cutaneous mast cells and BR cells, a poorly differentiated mast cell line from dog subcutaneous mastocytoma. Vet. Immunol. Immunopathol. 62:323-337.
31. Leal-Berumen, I., P. Conlon, and J. S. Marshall. 1994. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. J. Immunol. 152:5468-5476.
32. Mazzari, S., R. Canella, L. Petrelli, G. Marcolongo, and A. Leon. 1996. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300:227-236.
33. Hultsch, T., K. D. Müller, J. G. Meingassner, M. Grassberger, R. E. Schopf, and J. Knop. 1998. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin- dependent manner. Arch. Dermatol. Res. 290:501-507.
34. Assanasen, P. and R. M. Naclerio. 2002. Antiallergic anti-inflammatory effects of H1-antihistamine in humans. Clin. Allergy Immunol. 17:101-139.
35. Queralt, M., C. Brazís, M. Merlos, and A. Puigdemont. 1998. Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug Dev. Res. 44:49-55.
36. Ozaki, Y., J. Rui, Y. Tang, and M. Satake. 1997. Antiinflammatory effect of Forsythia suspense Vahl and its active fraction. Biol. Pharm. Bull. 20:861-864.
37. Janaki, S., V. Vijayasekaran, S. Viswanathan, and K. Balakrishna. 1999. Anti-inflammatory activity of Aglaia roxburghiana var. beddomei extract and trierpenes roxburghiadiol A and B. J. Ethnopharmacol. 67:45-51.
38. Moreno, L., R. Bello, E. Primo-Yufera, and J. Esplugues. 2002. Pharmacological properties of the methanol extract from Mentha suaveolens Ehrh. Phytother. Res. 1:S10-S13.
39. Lee, E. B., D. W. Li, J. E. Hyun, I. H. Kim, and W. K. Whang. 2001. Antiinflammatory activity of methanol extract of Kalopanax pictus bark and its fractions. J. Ethnopharmacol. 77:197-201.
40. Romagnani, S. 2000. The role of lymphocytes in allergic disease. J. Allergy Clin. Immunol. 105:399-408.
41. Romagnani, S. 2001. Cytokines and chemoattractants in allergic inflammation. Mol. Immunol. 38:881-885.